ABL2: A Non-Receptor Tyrosine Kinase in Cell Signaling and Cancer
Comprehensive genomic and functional overview of ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase) from NCBI, Ensembl, UniProt, OMIM, HGNC, COSMIC, and ClinVar.
Gene Information Card
| Symbol | ABL2 |
|---|---|
| Full Name | ABL proto-oncogene 2, non-receptor tyrosine kinase |
| Gene Type | protein-coding |
| Chromosomal Location | 1q25.2 |
| NCBI Gene ID | 27 ncbi.nlm.nih.gov/gene/27 |
| Ensembl ID | ENSG00000143384 |
| UniProt ID | P42684 |
| OMIM ID | 164690 |
| HGNC ID | 77 |
| Aliases | ARG, ABLL, Abelson-related gene |
Description
ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase) encodes a cytoplasmic tyrosine kinase that regulates cytoskeletal dynamics, cell adhesion, and migration. It shares structural homology with ABL1 and is implicated in cancer progression and neurological disorders.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Chronic Myeloid Leukemia (CML) | Fusion with BCR (rare) leading to constitutive kinase activation | PMID: 10666374 |
| Solid tumors (e.g., breast, lung) | Overexpression and aberrant activation promoting invasion | PMID: 21804562 |
| Intellectual disability | De novo missense variants affecting kinase activity | ClinVar: VCV000429586 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Lung | 8.3 | Low |
| Breast | 6.7 | Low |
| Testis | 15.2 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| K562 (CML) | 18.4 | High expression; BCR-ABL1 negative control |
| MCF7 (breast) | 9.1 | Moderate |
| HEK293 | 7.5 | Low |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| p.Gly2Arg | Missense | <0.1% | Impaired kinase activity (ClinVar) |
| p.Arg171Trp | Missense | <0.1% | Loss of function (ClinVar) |
| p.Glu255Lys | Missense | <0.1% | Gain of function (COSMIC) |
Mutation functional classification
Loss of Function (LOF)
Missense variants in the kinase domain (e.g., p.Gly2Arg) reduce catalytic activity.
Gain of Function (GOF)
Rare mutations (e.g., p.Glu255Lys) enhance kinase activity and promote oncogenic signaling.
Dominant Negative (DN)
Not well characterized; some truncating mutations may interfere with wild-type function.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Rho GTPase cycle (Reactome: R-HSA-194840)
• Signaling by Receptor Tyrosine Kinases (Reactome: R-HSA-9006934)
• FCERI mediated MAPK activation (Reactome: R-HSA-2871796)
Protein Summary
ABL2 (ARG) is a 1182-amino acid non-receptor tyrosine kinase with SH2, SH3, and actin-binding domains. It localizes to the cytoplasm and cytoskeleton, regulating cell motility and adhesion. Its kinase activity is tightly regulated; aberrant activation contributes to tumor invasion and metastasis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ABL2 Knockout HeLa Cell Line | EDJ-KQ20678 | Human | 27 | Details Get a Quote |
| ABL2 Knockout A-549 Cell Line | EDJ-KQ20677 | Human | 27 | Details Get a Quote |
| ABL2 Knockout HCT 116 Cell Line | EDJ-KQ19330 | Human | 27 | Details Get a Quote |
| ABL2 Knockout HEK293 Cell Line | EDJ-KQ17799 | Human | 27 | Details Get a Quote |